Table 2.

Keypoints and clinical impact of empagliflozin

Outcomes vs placebo:

Reduction in CV death (3.7% vs 5.9%, HR 0.62)

Reduction in all-cause mortality (5.7% vs 8.3%, HR 0.68)

Reduction in hospitalization for heart failure (2.7% vs 4.1%, HR 0.65)

Surrogate effects:

Osmotic diuresis

Lowers blood sugar: HbA1c reduction of −0.66%21

Lowers blood pressure: WMD reduction of −4.19 mmHg/−1.88 mmHg21

Lowers weight: 1.84 kg reduction21

Lowers waist circumference: ~2 cm reduction18

Decrease in pulse pressure: 2.3 mmHg reduction27

Increases HDL: increases ~2 mg/dL18

Decreases uric acid: decreases 0.4 mg/dL18

Abbreviations: CV, cardiovascular; HR, hazard ratio; HbA1c, hemoglobin A1C; WMD, weighted mean difference; HDL, high-density lipoprotein.